Investigational drug · Phase 2
Prizloncabtagene Autoleucel
Also called: C-CAR039
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL).
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "Prizloncabtagene Autoleucel"
First trial start
2023
Feb 22, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Prizloncabtagene Autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Large B Cell Lymphoma
- LBCL
- Diffuse Large B Cell Lymphoma (DLBCL)
- Relapse Diffuse Large B Cell Lymphoma
- High Grade B Cell Lymphoma
- FL
- HGBL
- Transformed Follicular Lymphoma (TFL)
- Primary Mediastinal B Cell Lymphoma
- PMBCL
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Prizloncabtagene Autoleucel" as an intervention, largest first.
Shanghai AbelZeta Ltd.Industry
NCT05800977 · 112 participants (planned) · Start Feb 22, 2023 · Primary completion Mar 31, 2027
Drug: Prizloncabtagene autoleucel · For: Relapsed/Refractory Large B-Cell Lymphoma
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 15 sites in all
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyNot yet recruiting
AbelZeta Inc.Industry
NCT07875413 · 55 participants (planned) · Start May 2027 · Primary completion Jun 2029
Drug: Prizloncabtagene Autoleucel · For: Large B Cell Lymphoma; LBCL; Diffuse Large B Cell Lymphoma (DLBCL) and 8 more
Sites: Gilbert, Arizona; La Jolla, California
Shanghai Tongji Hospital, Tongji University School of MedicineAcademic, hospital or other
NCT04317885 · 25 participants · Start Nov 5, 2019 · Primary completion Jun 30, 2023
Drug: Prizloncabtagene Autoleucel · For: Non-Hodgkin's B-cell Lymphoma
Sites: Shanghai, China
- A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's LymphomaStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT04693676 · 17 participants · Start Aug 3, 2020 · Primary completion Dec 31, 2023
Drug: Prizloncabtagene Autoleucel · For: Non-Hodgkin's B-cell Lymphoma
Sites: Hangzhou, China
Peking Union Medical College HospitalAcademic, hospital or other
NCT04655677 · 10 participants · Start Oct 30, 2020 · Primary completion Feb 28, 2024
Drug: Prizloncabtagene Autoleucel · For: B-cell Non-Hodgkin's Lymphoma
Sites: Beijing, China
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT04696432 · 7 participants · Start Nov 27, 2020 · Primary completion Jul 31, 2023
Drug: Prizloncabtagene autoleucel · For: Non-Hodgkin's B-cell Lymphoma
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.